Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest news

Trovagene announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial
San Diego, June 29th 2017 - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it has executed a supplier agreement with NerPharMa, S.r.l., a pharmaceutical manufacturing company and a subsidiary of Nerviano Medical Sciences S.r.l., in Milan, Italy, to manufacture drug product for PCM-075.
Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib "for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies."

Al prossimo AACR Nerviano Medical Sciences presenterà le novità su due efficaci nuovi inibitori oncologici, selettivi e tollerati

Nerviano, 31 marzo 2017 – Con un track record di 8 molecole licenziate in sei anni ed una robusta pipeline con diversi esempi dell’oncologia di precisione, il Campus di Nerviano Medical Sciences può vantare anche progetti in ricerca preclinica che stanno avanzando con successo e che rappresentano le prospettive future. Le nuove evidenze al prossimo Meeting dell’American Association for Cancer Research

Al prossimo AACR Annual Meeting, il più importante Congresso mondiale della ricerca oncologica che si svolgerà a Washington dall’1 al 5 aprile, Nerviano Medical Sciences presenterà alcuni nuovi risultati rilevanti ottenuti nel campo delle chinasi, una famiglie di proteine che normalmente regola diversi processi cellulari fisiologici, spesso anche determinante per la crescita “impazzita” della cellula tumorale.

I ricercatori descriveranno, in particolare, gli effetti antitumorali ottenuti nella fase preclinica di due nuove molecole proprietarie che colpiscono due diversi importanti bersagli terapeutici: RET, che è attivato in alcuni tumori tra cui quello del polmone, del colon e della tiroide e PERK, che avrebbe un ruolo importante nel mieloma multiplo.

Le ricerche effettuate nel Campus nervianese hanno permesso, infatti, la scoperta di NMS-E668 e NMS-E194, entrambe esempio dell’oncologia di precisione, che si sono dimostrate efficaci nel bloccare la crescita delle cellule tumorali.
NMS-E668 è un inibitore di RET che ha dimostrato un’attività preclinica molto potente e ben tollerata in diversi tumori dipendenti da questa chinasi. Potenza, efficacia e tollerabilità caratterizzano anche NMS-E194, inibitore della chinasi PERK, in modelli di mieloma multiplo.
Per entrambe le molecole procedono le analisi di ricerca preclinica propedeutiche all’eventuale sviluppo clinico.

NMS-E668 e NMS-E194 sono frutto della piattaforma chinasica di Nerviano Medical Sciences. Si tratta di un sistema integrato di know-how, tecnologie e proprietà intellettuale sviluppato negli anni dal Centro e basato, appunto, sulle proteine chinasi come bersagli molecolari. L’impiego di questa piattaforma permette al Campus di ricerca nervianese una cospicua sinergia nello sviluppo efficiente di nuovi farmaci antitumorali “intelligenti”, in grado di colpire le cellule malate e non quelle sane.

April 3, 2017, 1:00 PM  -  Session PO.ET06.07 - Growth Factor and Hormone Receptors as Therapeutic Targets
“2082. NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models”!/4292/presentation/3920

April 5, 2017, 8:00 AM  -  Session PO.ET06.01 - Oncogenes and Tumor Suppressors as Therapeutic Targets
“5163. Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma.”!/4292/presentation/4123

Trovagene and Nerviano Announce License Agreement for therapeutic candidate PCM-075

Nerviano, Italy (March 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a license agreement that grants Trovagene exclusive global development and commercialization rights to NMS-1286937, which Trovagene refers to as PCM-075. PCM-075 is an oral, investigative drug and a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1).

“We are excited to license PCM-075 and look forward to beginning a development program in patients with acute myeloid leukemia (AML),” said Bill Welch, CEO of Trovagene. “This transaction allows Trovagene to execute on our strategy to vertically integrate our ctDNA Precision Cancer Monitoring® (PCM) technology with precision cancer therapeutics by developing drugs where our deep understanding of tumor genomics may allow for effective targeting of appropriate cancer patients.”

“We are very pleased to start a collaboration with Trovagene, a world leader in precision medicine,” said Andrea Agazzi, President of the NMS Group. “Both Nerviano and Trovagene share the common goal of developing innovative new drugs for cancer patients. We're proud of this new important agreement as a further confirmation of our commitment to develop high level innovation through partnering. Our continuously increasing track record involves, in fact, companies at a worldwide level like Trovagene.”

Under the terms of the license agreement, Trovagene will assume sole responsibility for global development and commercialization of PCM-075. Nerviano will receive an upfront payment of $2.0 million, as well as development and regulatory-based milestone payments and royalty payments on future net sales of PCM-075. Nerviano is the current manufacturer for bulk and finished drug for PCM-075 and Trovagene has all rights to manufacture bulk and finished goods.

PLK1 is over-expressed in several different tumor types, including breast, prostate, ovarian, lung, gastric and colon cancers, as well as hematological malignancies. A phase 1 safety study of PCM-075 was successfully completed in patients with advanced metastatic disease. Trovagene plans to develop PCM-075 initially in AML, where both Trovagene and Nerviano believe PCM-075’s target selectivity for PLK1, along with its oral availability, and shorter half-life as compared to other polo-like-kinase inhibitors, may be advantageous features of the drug.

Trovagene has significant experience and expertise with biomarkers and technology in cancer, including AML. Trovagene is the patent holder of NPM1 for diagnosis and monitoring of patients. NPM1-mutated AML is a founder genetic marker in leukemia and accounts for approximately one-third of all AML patients. Trovagene will use its PCM technology to profile other dominant AML markers, such as FLT3, DNMT3A, NRAS, and KIT, to identify and measure patient therapy response.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene's strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2016 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in...

San Diego - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib—the company's investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions—were published in the journal Cancer Discovery. The studies showed entrectinib to be well tolerated, with responses observed in non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma as early as four weeks after first treatment and lasting as long as 2.5 years and still ongoing. Entrectinib is currently being studied in a separate registration-enabling global Phase 2 basket clinical trial known as STARTRK-2. ()

Vinaora Nivo SliderVinaora Nivo Slider

Nerviano Medical Sciences

Nerviano Medical SciencesHeart of the innovative Group focused on the identification of new therapeutic strategies, research and development of new drugs, shapes the future of the oncology.


AcceleraAn Italian preclinical research Company, recognized and certified, all over the world provides high standard integrated services, with reliability and international compliance.


CliossWith an extensive experience, Clioss partners worldwide Biopharma, Biotech and Research Institutions for full cycle drug development from First-Time-In-Man.


NerpharmaConsolidated know-how, the highest quality standards characterize the offered services: for the formulation, the registration and the production of the active principle.

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.